Department of Surgical Oncology, Institute Gustave Roussy, Villejuif, France.
Dig Surg. 2011;28(2):114-20. doi: 10.1159/000323820. Epub 2011 Apr 29.
Missing metastases, also called vanishing or disappearing liver metastases, concern about 5% of patients with colorectal liver metastasis undergoing chemotherapy, and this phenomenon is likely to become more frequent in the near future, with the widespread use of highly efficient chemotherapy. As their definition is highly dependent on the quality of initial imaging, a DLM on preoperative computed tomography scan should be systematically confirmed by a second imaging modality, ideally magnetic resonance imaging. It is important to note that a complete clinical response does not mean a complete pathologic response. Currently, there are no absolute criteria of a complete pathologic response. However, treatment with neoadjuvant and adjuvant hepatic arterial infusion in patients <60 years old with an initially low carcinoembryonic antigen level that normalizes under chemotherapy and who have no detectable lesion on both computed tomography and magnetic resonance imaging is probably more likely to yield a complete pathologic response. Whatever their treatment, patients with DLM run a high risk of recurrence that could be decreased with the use of HAI. Despite a high recurrence rate, the overall 5-year survival rate of patients with DLM ranges from 40 to 80%. Having a DLM should no longer be a contraindication to hepatic surgery since long-term survival is expected in these highly chemosensitive patients. The use of adjuvant HAI in addition to efficient systemic chemotherapy could reduce the risk of hepatic relapse.
肝转移灶消失,也称为“消失性肝转移”,约占接受化疗的结直肠癌肝转移患者的 5%,随着高效化疗的广泛应用,这种现象在不久的将来可能会更加频繁。由于其定义高度依赖于初始影像学的质量,术前计算机断层扫描(CT)上的肝转移瘤消失应通过第二种影像学方法(理想情况下为磁共振成像)来系统地确认。需要注意的是,完全临床缓解并不意味着完全病理缓解。目前,还没有完全病理缓解的绝对标准。然而,对于初始癌胚抗原(CEA)水平较低、在化疗下恢复正常且 CT 和磁共振成像均未检测到病变的<60 岁患者,采用新辅助和辅助肝动脉灌注治疗,可能更有可能获得完全病理缓解。无论接受何种治疗,肝转移灶消失的患者复发风险很高,肝动脉灌注化疗(HAI)可能会降低这种风险。尽管复发率较高,但肝转移灶消失患者的 5 年总生存率仍为 40%至 80%。肝转移灶消失不应再成为肝切除术的禁忌证,因为这些高度化疗敏感的患者有望长期生存。除了有效的全身化疗外,辅助 HAI 的应用可以降低肝内复发的风险。